Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

• Status: Completed
• Trial end date: 2014-12-01

Summary

To evaluate the toxicity and tolerability of this tandem autologous/allogeneic transplant approach for patients with advanced stage multiple myeloma.

• Phase: Phase 2

Details

• Lead Sponsor: Stanford University
• Treatments: Acetaminophen; Antilymphocyte Serum; Cyclophosphamide; Cyclosporine; Cyclosporins; Diphenhydramine; Hydrocortisone; Lenograstim; Mechlorethamine; Melphalan; Methylprednisolone Hemisuccinate; Mycophenolate mofetil; Mycophenolic Acid; Promethazine; Thymoglobulin